Dr. Michael J. Georgetson, MD
Gastroenterology (Gastroenterology Physician)
- Medicare participating
At a glance
- Medical school
- Jefferson Medical College of Thomas Jefferson University (1985)
- Years since graduation
- 41
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 553
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1985Medical school: Jefferson Medical College of Thomas Jefferson University
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Gastroenterology Physician primary
PA license MD036907E · NY license 174652-1
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Robert PAcker Hospital Sayre, PA
- Corning Hospital Corning, NY
- Guthrie Cortland Regional Medical Center Cortland, NY
Medical groups
- Guthrie Medical Group PC (795 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 553
- Services billed
- 1,140
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 202 | 201 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 181 | 177 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 151 | 145 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | 108 | 63 |
| Balloon dilation of esophagus, stomach, and/or upper small bowel using a flexible endoscope, less than 3.0 cm | 93 | 76 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 83 | 76 |
| Colorectal cancer screening; colonoscopy on individual at high risk | 81 | 80 |
| Biopsy of large bowel using a flexible endoscope | 66 | 66 |
| Established patient office or other outpatient visit, 20-29 minutes | 47 | 44 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 33 | 33 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Gavilyte-G (peg3350/sod sulf,bicarb,cl/kcl) Other prescribers in Sayre, PA | 84 |
| Lansoprazole Other prescribers in Sayre, PA | 82 |
| Peg-3350 And Electrolytes (peg3350/sod sulf,bicarb,cl/kcl) Other prescribers in Sayre, PA | 73 |
| Omeprazole Other prescribers in Sayre, PA | 62 |
| Pantoprazole Sodium Other prescribers in Sayre, PA | 60 |
| Sucralfate Other prescribers in Sayre, PA | 20 |
| Humira(Cf) Pen (adalimumab) Other prescribers in Sayre, PA | 14 |
| Linzess (linaclotide) Other prescribers in Sayre, PA | 14 |
| Mesalamine Other prescribers in Sayre, PA | 13 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 1 companies. The companies reported $23,209 in research payments for these studies, mostly to the institutions running them.
- A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC)
AbbVie Inc. · Active, not recruiting · NCT03006068 - M14-533 - A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC)
AbbVie Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.